Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently commented on RVNC. Barclays reduced their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Mizuho cut their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. HC Wainwright restated a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Trading Down 0.6 %

Shares of Revance Therapeutics stock opened at $3.06 on Friday. The stock’s fifty day moving average price is $4.12 and its 200-day moving average price is $4.48. The firm has a market cap of $319.43 million, a P/E ratio of -1.59 and a beta of 0.81. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. Analysts forecast that Revance Therapeutics will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Revance Therapeutics

A number of large investors have recently modified their holdings of RVNC. Bank of New York Mellon Corp boosted its stake in Revance Therapeutics by 22.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 373,015 shares of the biopharmaceutical company’s stock worth $959,000 after purchasing an additional 68,451 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Revance Therapeutics by 47.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,961 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 10,638 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Revance Therapeutics by 11.6% during the second quarter. Rhumbline Advisers now owns 136,347 shares of the biopharmaceutical company’s stock worth $350,000 after buying an additional 14,191 shares during the period. CM Management LLC raised its stake in Revance Therapeutics by 60.0% in the 2nd quarter. CM Management LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $1,028,000 after acquiring an additional 150,000 shares during the last quarter. Finally, Arizona State Retirement System raised its stake in Revance Therapeutics by 27.6% in the 2nd quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 5,996 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.